Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Completed · Not applicable

Conditions studied: Miscarriage, Recurrent, Abortion, Habitual

In brief

Recurrent miscarriage is a prevalent reproductive problem that affects many couples who are trying to establish a family. This clinical study will evaluate the effectiveness of intravenous immunoglobulin (IVIG) in improving the live birth rate in couples who suffer from secondary recurrent miscarriage. This study will help in providing an answer to the question of whether IVIG is helpful in secondary recurrent miscarriage.

Key facts

Study ID

NCT00606905

Run by

University of Chicago

People needed

82

Starts

1999-11-01

Expected to finish

2010-01-01

Last updated by the study team

2012-10-08

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Couple has a history of unexplained secondary recurrent miscarriage.
• Most recent pregnancy occurred within one year of discontinuing contraception.

You may not qualify if…

• Maternal IgA deficiency
• Maternal history of immunoglobulin hypersensitivity.
• Maternal contraindication to pregnancy.
• Evidence of active hepatitis or immunocompromised state in either partner.
• Concomitant use of medication(s) for treatment of recurrent miscarriage, such as but not limited to progesterone, clomiphene citrate, acetylsalicylic acid, heparin, glucocorticoids or hCG injections.

Where it is running

• The University of Chicago — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.